Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

PSGL-1 Immune Checkpoint Inhibition for CD4+ T Cell Cancer Immunotherapy

Frontiers in Immunology(2021)10.3389/fimmu.2021.636238Source: DataRank Database

PSGL-1 Immune Checkpoint Inhibition for CD4+ T Cell Cancer Immunotherapy is a research paper published in Frontiers in Immunology (2021). On theSindex it has a DataRank of 0. It has been cited 53 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access53 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)OA: goldTopics (36)IDs (PubMed, PMC)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Karla M. Viramontes,Emily N. Neubert ORCID,Roberto Tinoco ORCID,Julia M. DeRogatis ORCID

Live enrichment

PubMed:33708224 PMC:PMC7940186

NIAID NIH HHS

Grant: R01 AI137239

NIAID NIH HHS

Grant: T32 AI007319

NCI NIH HHS

Grant: T32 CA009054

National Institutes of Health

Grant: 5T32AI007319-35

Virus-host interactions: a multi-scale training program

National Institutes of Health

Grant: 3R01AI137239-02S1

PSGL-1 mechanisms of T cell exhaustion

National Institutes of Health

Grant: 2T32CA009054-16

CARCINOGENESIS

National Institutes of Health

U.S. Department of Defense

Melanoma Research Alliance

goldLicense: CC BY

Unpaywallhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.636238/pdf

Europe_PMChttps://europepmc.org/articles/PMC7940186

Europe_PMChttps://europepmc.org/articles/PMC7940186?pdf=render

https://doi.org/10.3389/fimmu.2021.636238

https://pubmed.ncbi.nlm.nih.gov/33708224

Fields of Study

0301 basic medicine03 medical and health sciences

MeSH Terms

CD4-Positive T-LymphocytesLymphocytes, Tumor-InfiltratingAnimalsMice, KnockoutHumansMiceNeoplasmsMembrane GlycoproteinsSignal TransductionPhenotypeMolecular Targeted TherapyTumor MicroenvironmentImmune Checkpoint Inhibitors

Keywords

Anti-tumor immunityCd4+ T CellsCancer ImmunologyPsgl-1Immune CheckpointsCD4-Positive T-LymphocytesMice, KnockoutMembrane GlycoproteinsImmunologyRC581-607MiceLymphocytes, Tumor-InfiltratingPhenotypeNeoplasmsTumor MicroenvironmentAnimalsHumansMolecular Targeted TherapyImmunologic diseases. AllergyImmune Checkpoint InhibitorsSignal Transduction

Sustainable Development Goals

SDG 3: 3. Good health

PSGL-1 Immune Checkpoint Inhibition for CD4+ T Cell Cancer Immunotherapy

FAIR Checklist

Authors (4)

Funding (9 grants)

Open Access

Topics

Annotations (Europe PMC)